Current Pain and Headache Reports

, Volume 7, Issue 5, pp 342–347 | Cite as

Fibromyalgia, hepatitis C infection, and the cytokine connection

  • Mollie E. Thompson
  • André Barkhuizen


Fibromyalgia and chronic hepatitis C infection share many clinical features including prominent somatic complaints such as musculoskeletal pain and fatigue. There is a growing body of evidence supporting a link between cytokines and somatic complaints. This review discusses alterations of cytokines in fibromyalgia, including increased serum levels of interleukin (IL)-2, IL-2 receptor, IL-8, IL-1 receptor antagonist; increased IL-1 and IL-6 produced by stimulated peripheral blood mononuclear cell in patients with FM for longer than 2 years; increased gp130, which is a neutrophil cytokine transducing protein; increased soluble IL-6 receptor and soluble IL-1 receptor antagonist only in patients with fibromyalgia who are depressed; and IL-1 β, IL-6, and TNF-α by reverse transcriptase-polymerase chain reaction in skin biopsies of some patients with fibromyalgia. In addition, this review describes the mechanism by which alterations in cytokines in fibromyalgia and chronic hepatitis C infection can produce hyperalgesia and other neurally mediated symptoms through the presence of cytokine receptors on glial cells and opiate receptors on lymphocytes and the influence of cytokines on the hypothalamus-pituitaryadrenal axis such as IL-1, IL-6, and TNF-α activating and IL-2 and IFN-α down-regulating the HPA axis, respectively. The association between chronic hepatitis C infection and fibromyalgia is discussed, including a description of key cytokine changes in chronic hepatitis C infection. Future studies are encouraged to further characterize these immunologic alterations with potential pathophysiologic and therapeutic implications.


Chronic Hepatitis Fibromyalgia Musculoskeletal Pain Lyme Disease Tender Point 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Rivera J, de Diego A, Trinchet M, Garcia Monforte A: Fibromyalgia-associated hepatitis C virus infection. Br J Rheumatol 1997, 36:981–985.PubMedCrossRefGoogle Scholar
  2. 2.
    Buskila D, Shnaider A, Neumann L, et al.: Musculoskeletal manifestations and autoantibody profile in 90 hepatitis C virus infected Israeli patients. Semin Arthritis Rheum 1998, 28:107–113.PubMedCrossRefGoogle Scholar
  3. 3.
    Wolfe F, Simons DG, Fricton J, et al.: The fibromyalgia and myofascial pain syndromes: a preliminary study of tender points and trigger points in persons with fibromyalgia, myofascial pain syndrome and no disease. J Rheumatol 1992, 19:944–951.PubMedGoogle Scholar
  4. 4.
    Reiffenberger DH, LH: Fibromyalgia syndrome: a review. Am Fam Physician 1996, 53:1698–1712.PubMedGoogle Scholar
  5. 5.
    Wolfe F, Ross K, Anderson J, et al.: The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum 1995, 38:19–28.PubMedCrossRefGoogle Scholar
  6. 6.
    Watkins LR, Maier SF: The pain of being sick: implications of immune-to-brain communication for understanding pain. Annu Rev Psychol 2000, 51:29–57. Excellent review of the relationship between the immune system and the central nervous system in pain modulation.PubMedCrossRefGoogle Scholar
  7. 7.
    Pillemer SR, Bradley LA, Crofford LJ, et al.: The neuroscience and endocrinology of fibromyalgia. Arthritis Rheum 1997, 40:1928–1939.PubMedCrossRefGoogle Scholar
  8. 8.
    Caro XJ: Is there an immunologic component to the fibrositis syndrome? Rheum Dis Clin North Am 1989, 15:169–186.PubMedGoogle Scholar
  9. 9.
    Wallace DJ, Peter JB, Bowman RL, et al.: Fibromyalgia, Cytokines, Fatigue Syndromes and Immune Regulation. New York: Raven Press Ltd; 1990.Google Scholar
  10. 10.
    Matsuda T, Fukada T, Takahashi-Tezuka M, et al.: Activation of Fes tyrosine kinase by gp130, an interleukin-6 family cytokine signal transducer, and their association. J Biol Chem 1995, 270:11037–11039.PubMedCrossRefGoogle Scholar
  11. 11.
    Narazaki M, Yasukawa K, Saito T, et al.: Soluble forms of the interleukin-6 signal-transducing receptor component gp130 in human serum possessing a potential to inhibit signals through membrane-anchored gp130. Blood 1993, 82:1120–1126.PubMedGoogle Scholar
  12. 12.
    Watkins LR, Goehler LE, Relton J, et al.: Mechanisms of tumor necrosis factor-alpha (TNF-alpha) hyperalgesia. Brain Res 1995, 692:244–250.PubMedCrossRefGoogle Scholar
  13. 13.
    Wallace DJ, Bowman RL, Wormsley SB, Peter JB: Cytokines and immune regulation in patients with fibrositis. Arthritis Rheum 1989, 32:1334–1335.PubMedCrossRefGoogle Scholar
  14. 14.
    Watkins LR, Wiertelak EP, Goehler LE, et al.: Characterization of cytokine-induced hyperalgesia. Brain Res 1994, 654:15–26.PubMedCrossRefGoogle Scholar
  15. 15.
    Oka T, Oka K, Hosoi M, Hori T: Intracerebroventricular injection of interleukin-6 induces thermal hyperalgesia in rats. Brain Res 1995, 692:123–128.PubMedCrossRefGoogle Scholar
  16. 16.
    Cunha FQ, Lorenzetti BB, Poole S, Ferreira SH: Interleukin-8 as a mediator of sympathetic pain. Br J Pharmacol 1991, 104:765–767.PubMedGoogle Scholar
  17. 17.
    Spath-Schwalbe E, Hansen K, Schmidt F, et al.: Acute effects of recombinant human interleukin-6 on endocrine and central nervous sleep functions in healthy men. J Clin Endocrinol Metab 1998, 83:1573–1579.PubMedCrossRefGoogle Scholar
  18. 18.
    Chrousos GP: The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation. N Engl J Med 1995, 332:1351–1362.PubMedCrossRefGoogle Scholar
  19. 19.
    Gur A, Karakoc M, Nas K, et al.: Cytokines and depression in cases with fibromyalgia. J Rheumatol 2002, 29:358–361.PubMedGoogle Scholar
  20. 20.
    Wallace DJ, Linker-Israeli M, Hallegua D, et al.: Cytokines play an aetiopathogenetic role in fibromyalgia: a hypothesis and pilot study. Rheumatology (Oxford) 2001, 40:743–749.CrossRefGoogle Scholar
  21. 21.
    Maes M, Libbrecht I, Van Hunsel F, et al.: The immune-inflammatory pathophysiology of fibromyalgia: increased serum soluble gp130, the common signal transducer protein of various neurotrophic cytokines. Psychoneuroendocrinology 1999, 24:371–383.PubMedCrossRefGoogle Scholar
  22. 22.
    Salemi S, Rethage J, Wollina U, et al.: Detection of interleukin 1beta (IL-1beta), IL-6, and tumor necrosis factor-alpha in skin of patients with fibromyalgia. J Rheumatol 2003, 30:146–150.PubMedGoogle Scholar
  23. 23.
    Buchwald D, Goldenberg DL, Sullivan JL, Komaroff AL: The “chronic, active Epstein-Barr virus infection” syndrome and primary fibromyalgia. Arthritis Rheum 1987, 30:1132–1136.PubMedCrossRefGoogle Scholar
  24. 24.
    Dinerman H, Steere AC: Lyme disease associated with fibromyalgia. Ann Intern Med 1992, 117:281–285.PubMedGoogle Scholar
  25. 25.
    Buskila D, Gladman DD, Langevitz P, et al.: Fibromyalgia in human immunodeficiency virus infection. J Rheumatol 1990, 17:1202–1206.PubMedGoogle Scholar
  26. 26.
    Leventhal LJ, Naides SJ, Freundlich B: Fibromyalgia and parvovirus infection. Arthritis Rheum 1991, 34:1319–1324.PubMedCrossRefGoogle Scholar
  27. 27.
    Nelson DR: The immunopathogenesis of hepatitis C virus infection. Clin Liver Dis 2001, 5:931–953. In-depth review of the immune response to hepatitis C infection with emphasis on the role of Th1 and Th2 cytokine responses.PubMedCrossRefGoogle Scholar
  28. 28.
    Koziel MJ: Cytokines in viral hepatitis. Semin Liver Dis 1999, 19:157–169.PubMedCrossRefGoogle Scholar
  29. 29.
    Barkhuizen A, Bennett RM: Hepatitis C infection presenting with rheumatic manifestations. J Rheumatol 1997, 24:1238–1239.PubMedGoogle Scholar
  30. 30.
    Barkhuizen A, Rosen HR, Wolf S, et al.: Musculoskeletal pain and fatigue are associated with chronic hepatitis C: a report of 239 hepatology clinic patients. Am J Gastroenterol 1999, 94:1355–1360.PubMedGoogle Scholar
  31. 31.
    Cacoub P, Poynard T, Ghillani P, et al.: Extrahepatic manifestations of chronic hepatitis C. MULTIVIRC Group. Multidepartment Virus C. Arthritis Rheum 1999, 42:2204–2212.PubMedCrossRefGoogle Scholar
  32. 32.
    Granges G, Littlejohn G: Pressure pain threshold in pain-free subjects, in patients with chronic regional pain syndromes, and in patients with fibromyalgia syndrome. Arthritis Rheum 1993, 36:642–646.PubMedCrossRefGoogle Scholar
  33. 33.
    Kosek E, Hansson P: Modulatory influence on somatosensory perception from vibration and heterotopic noxious conditioning stimulation (HNCS) in fibromyalgia patients and healthy subjects. Pain 1997, 70:41–51.PubMedCrossRefGoogle Scholar
  34. 34.
    Lautenbacher S, Rollman GB: Possible deficiencies of pain modulation in fibromyalgia. Clin J Pain 1997, 13:189–196.PubMedCrossRefGoogle Scholar
  35. 35.
    Staud R, Vierck CJ, Cannon RL, et al.: Abnormal sensitization and temporal summation of second pain (wind-up) in patients with fibromyalgia syndrome. Pain 2001, 91:165–175.PubMedCrossRefGoogle Scholar
  36. 36.
    Buskila D, Shnaider A, Neumann L, et al.: Fibromyalgia in hepatitis C virus infection: another infectious disease relationship. Arch Intern Med 1997, 157:2497–2500.PubMedCrossRefGoogle Scholar
  37. 37.
    Hsu VM, Patella SJ, Sigal LH: “Chronic Lyme disease” as the incorrect diagnosis in patients with fibromyalgia. Arthritis Rheum 1993, 36:1493–1500.PubMedCrossRefGoogle Scholar
  38. 38.
    Koziel MJ, Dudley D, Wong JT, et al.: Intrahepatic cytotoxic T lymphocytes specific for hepatitis C virus in persons with chronic hepatitis. J Immunol 1992, 149:3339–3344.PubMedGoogle Scholar
  39. 39.
    Nelson DR, Marousis CG, Davis GL, et al.: The role of hepatitis C virus-specific cytotoxic T lymphocytes in chronic hepatitis C. J Immunol 1997, 158:1473–1481.PubMedGoogle Scholar
  40. 40.
    Foster GR, Ackrill AM, Goldin RD, et al.: Expression of the terminal protein region of hepatitis B virus inhibits cellular responses to interferons alpha and gamma and doublestranded RNA. Proc Natl Acad Sci U S A 1991, 88:2888–2892.PubMedCrossRefGoogle Scholar
  41. 41.
    Napoli J, Bishop GA, McGuinness PH, et al.: Progressive liver injury in chronic hepatitis C infection correlates with increased intrahepatic expression of Th1-associated cytokines. Hepatology 1996, 24:759–765.PubMedCrossRefGoogle Scholar
  42. 42.
    Fukuda R, Ishimura N, Ishihara S, et al.: Intrahepatic expression of pro-inflammatory cytokine mRNAs and interferon efficacy in chronic hepatitis C. Liver 1996, 16:390–399.PubMedGoogle Scholar
  43. 43.
    Cacciarelli TV, Martinez OM, Gish RG, et al.: Immunoregulatory cytokines in chronic hepatitis C virus infection: pre- and post-treatment with interferon alpha. Hepatology 1996, 24:6–9.PubMedCrossRefGoogle Scholar
  44. 44.
    Cribier B, Schmitt C, Rey D, et al.: Production of cytokines in patients infected by hepatitis C virus. J Med Virol 1998, 55:89–91.PubMedCrossRefGoogle Scholar

Copyright information

© Current Science Inc 2003

Authors and Affiliations

  • Mollie E. Thompson
    • 1
  • André Barkhuizen
  1. 1.Division of Arthritis and Rheumatic DiseasesOregon Health & Science UniversityPortlandUSA

Personalised recommendations